Medication info
Diabex XR Extended-Release Tablet 1000 mg (Metformin Hydrochloride)

Diabex XR Extended-Release Tablet 1000 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceuticals
Appearance
White to off-white, oval, biconvex extended-release tablet
Packaging
60 tablets (10 tablets/PTP) × 6
Approval status
Active

MFDS item code 201002151 · Approved 2010.03.18 · Insurance code 641604640

Summary

Main use
Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin in the blood should be measured approximately every 3 months. - The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this medicine must be discontinued immediately.

Ingredients

Importer
Daewoong Pharmaceuticals

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise

  • Type 2 diabetes with inadequate blood sugar control
View approved original text

This medication is used for adult patients with type 2 diabetes whose blood sugar control is insufficient with diet and exercise alone, especially those who are overweight. It can be taken alone or in combination with other oral hypoglycemic agents or insulin treatment, allowing for flexible treatment tailored to the patient’s condition. It effectively helps manage diabetes by controlling blood sugar levels.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin in the blood should be measured approximately every 3 months. - The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this medicine must be discontinued immediately.

Precautions

This medication may rarely cause a serious condition called lactic acidosis, which can lead to death. Caution is necessary when used in conjunction with insulin or sulfonylureas, as severe hypoglycemia may occur. This medication should not be used in patients with moderate to severe renal impairment or those in acute conditions such as dehydration, serious infections, or acute myocardial infarction. It should be discontinued before and after tests involving acute heart failure or radiologic iodine contrast agents and may only be resumed after renal function is confirmed to be normal. Patients allergic to this medication’s components or to biguanide class medications should not use it. It is not indicated for patients with type 1 diabetes or a history of lactic acidosis or ketosis. In cases of severe infections, trauma, or pre-and post-surgery, this medication should be temporarily discontinued and resumed only after the patient’s condition stabilizes. Caution is also warranted for patients with poor nutritional status, impaired liver function, or excessive alcohol intake. In pregnant women at risk of placental insufficiency or preeclampsia, the use of this medication should be avoided. During therapy, if dietary intake is irregular or insufficient, intense exercise is undertaken, or other medications are used concurrently, the risks of lactic acidosis and hypoglycemia may increase, thus requiring careful monitoring. Gastrointestinal disturbances such as nausea, vomiting, and diarrhea are common at the beginning of treatment but usually improve over time. This medication is excreted through the kidneys; therefore, regular renal function assessments should be conducted, and if abnormalities are found, the medication should be discontinued. Alcohol can increase the risk of side effects, so excessive consumption should be avoided. If blood sugar control becomes difficult or hypoglycemic symptoms occur, immediate consultation with healthcare providers is necessary. Elderly patients are at higher risk of diminished renal function, so dosage adjustments and regular renal function monitoring need to be performed. This medication may be used during pregnancy for blood sugar control, but careful observation of fetal growth is necessary and is not recommended during breastfeeding. In cases of overdose, dialysis may be required, and prompt medical attention is necessary. This medication should be swallowed whole without chewing or crushing, and it is normal for part of the tablet to pass in the stool. There is potential for interactions with other medications, so patients should inform healthcare providers about any other medications they are taking.

Side effects

  • Lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. A recommended storage temperature is between 1 degree and 30 degrees Celsius to maintain its effectiveness over time.

Appearance and packaging

Appearance

White to off-white, oval, biconvex extended-release tablet

Package unit

60 tablets (10 tablets/PTP) × 6

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.